<DOC>
	<DOCNO>NCT01998984</DOCNO>
	<brief_summary>This randomise , double-blind , parallel group , vehicle control , 8-week phase 2 trial . The objective evaluate efficacy ingenol mebutate gel 0.06 % daily treatment 2 , 3 4 consecutive day compare vehicle gel</brief_summary>
	<brief_title>Efficacy Safety Ingenol Mebutate Gel 0.06 % When Applied Once Daily 2 , 3 4 Consecutive Days Treatment Area Approximately 250 cm2 Trunk Extremities Subjects With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects 5 20 clinically typical , visible discrete AKs within contiguous area approximately 250 cmÂ² sundamaged skin either trunk ( except chest ) , extremities Location treatment area ( trunk ( except chest ) extremity ) within 5 cm incompletely heal wound , within 5 cm suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) Prior treatment ingenol mebutate within select treatment area Lesions treatment area : atypical clinical appearance ( e.g. , hypertrophic , hyperkeratotic cutaneous horn ) and/or , recalcitrant disease ( e.g. , respond cryotherapy two previous occasion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>